

May 5, 2023

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549

Attention: Jimmy McNamara

Re: BELITE BIO, INC.
Registration Statement on Form F-3
Filed May 1, 2023
File No. 333-271549

Ladies and Gentlemen:

Pursuant to Rules 460 and 461 of the Rules and Regulations of the U.S. Securities and Exchange Commission (the “**Commission**”) under the Securities Act of 1933, as amended, Belite Bio, Inc (the “**Company**”), hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-3 (the “**Registration Statement**”) be accelerated to, and that the Registration Statement become effective at, 4:00 PM (Eastern time) on May 9, 2023, or as soon thereafter as practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Robert Plesnarski (+1 (202) 383-5149) or Portia Ku (+1 (212) 326-2168) of O’Melveny & Myers LLP, counsel to the Company. Thank you for your assistance with this matter.

[Signature page follows]

Very truly yours,

BELITE BIO, INC

By: /s/ Yu-Hsin Lin

Name: Yu-Hsin Lin

Title: Chief Executive Officer and Chairman
